Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.

DOI Web Site 被引用文献20件
  • H Shiraga
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • W Min
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • W J VanDusen
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • M D Clayman
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • D Miner
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • C H Terrell
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • J R Sherbotie
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • J W Foreman
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • C Przysiecki
    Department of Pediatrics, University of Pennsylvania, Philadelphia.
  • E G Neilson
    Department of Pediatrics, University of Pennsylvania, Philadelphia.

抄録

<jats:p>The majority of human urinary stones are primarily composed of calcium salts. Although normal urine is frequently supersaturated with respect to calcium oxalate, most humans do not form stones. Inhibitors are among the multiple factors that may influence the complex process of urinary stone formation. We have isolated an inhibitor of calcium oxalate crystal growth from human urine by monoclonal antibody immunoaffinity chromatography. The N-terminal amino acid sequence and acidic amino acid content of this aspartic acid-rich protein, uropontin, are similar to those of other pontin proteins from bone, plasma, breast milk, and cells. The inhibitory effect of uropontin on calcium oxalate crystal growth in vitro supports the concept that pontins may have a regulatory role. This function would be analogous to that of other members of the aspartic acid-rich protein superfamily, which stereospecifically regulate the mineralization fronts of calcium-containing crystals.</jats:p>

収録刊行物

被引用文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ